Disease-Associated Microglia (DAM) represent a distinct activation state of brain immune cells that emerges in response to neurodegeneration. Originally identified in mouse models of Alzheimer's disease through single-cell RNA sequencing, DAM are characterized by a unique transcriptional signature that distinguishes them from both homeostatic microglia and classically activated inflammatory microglia.
The DAM phenotype represents a continuum of microglial activation states ranging from early-stage "pre-DAM" to fully activated DAM. This activation is driven by a combination of aging-related changes, genetic risk factors (particularly TREM2 and APOE variants), and the presence of pathological protein aggregates.
DAM activation occurs through a stepwise process:
The initial DAM stage is triggered independently of TREM2 signaling:
- Downregulation of homeostatic microglial genes (P2ry12, Tmem119, Cx3cr1)
- Upregulation of disease-related genes involved in lipid metabolism and phagocytosis
- Initial morphological changes toward an activated state
Full DAM activation requires TREM2 signaling:
- TREM2 activation enhances phagocytic capacity
- Migration toward pathological lesions
- Upregulation of genes involved in lipid metabolism and lysosomal function
- APOE-mediated feedback loop driving the DAM transcriptional program
TREM2 ligands include phospholipids on apoptotic neurons, amyloid-beta oligomers and fibrils, and APOE. The receptor signals through DAP12 (TYROBP) to activate PI3K/Akt and Syk-dependent pathways.
The DAM signature includes several hallmark genes:
- Itgax (CD11c) — integrin involved in phagocytosis
- Clec7a (Dectin-1) — pattern recognition receptor
- Spp1 (osteopontin) — extracellular matrix protein
- Axl and Tyro3 — TAM receptor kinases for efferocytosis
- Cd9 — tetraspanin involved in cell adhesion
- Gpnmb — glycoprotein nonmetastatic melanoma protein B
DAM are most extensively characterized in AD models and human tissue:
- Plaque association: DAM preferentially cluster around amyloid-beta plaques, forming a barrier that compacts plaques and limits their toxic halo
- Amyloid clearance: TREM2-dependent phagocytosis of amyloid fibrils and damaged myelin
- Plaque seeding: Elevating TREM2 reduces amyloid seeding and suppresses DAM in early disease stages
- Human validation: Single-cell RNA sequencing of human AD brains confirms the presence of DAM-like populations
DAM are found in ALS spinal cord near degenerating motor neurons:
- SOD1 mutant mice show progressive DAM accumulation
- The DAM signature in ALS overlaps substantially with AD
- TREM2 deficiency accelerates disease progression in SOD1 mice
In PD and related synucleinopathies:
- DAM-like microglia are found near alpha-synuclein pathology
- LRRK2 mutations affect microglial inflammatory responses and DAM activation
- GBA mutations alter lipid metabolism in microglia, potentially affecting DAM function
- Amyloid compaction: DAM form a protective barrier around amyloid-beta plaques
- Phagocytic clearance: Enhanced phagocytosis of cellular debris and protein aggregates
- Neurotrophic support: DAM express growth factors and survival signals
- TREM2 loss-of-function worsens disease: TREM2 knockout exacerbates neurodegeneration
- Chronic inflammation: Sustained DAM activation drives chronic neuroinflammation
- Excessive synaptic pruning: DAM-mediated complement-dependent phagocytosis may contribute to synaptic loss
- Tau propagation: DAM may facilitate tau propagation through exosome release
- Oxidative damage: Activated DAM produce reactive oxygen species
DAM function is context-dependent:
- Disease stage: DAM may be protective early but become dysfunctional with chronic activation
- Brain region: DAM responses vary by brain region
- Genetic background: APOE genotype influences DAM function
TREM2 represents a prime therapeutic target for modulating DAM:
- TREM2 agonists: Enhance phagocytosis and neuroprotection
- TREM2 antagonists: Block excessive TREM2 signaling to reduce harmful inflammation
- Gene therapy: Viral delivery of TREM2 variants
Modulating APOE function offers another therapeutic avenue:
- APOE4 modifiers: Reduce APOE4 expression or enhance its function
- APOE mimetics: Peptides that mimic APOE's beneficial functions
- Lipid supplementation: Provide essential lipids to enhance microglial function
The complement system's role in synaptic pruning makes it an attractive target:
- C1q inhibitors: Reduce complement-mediated synaptic loss
- C3 inhibitors: Protect neurons from complement-mediated damage
- CR3 blockers: Reduce excessive phagocytosis of synapses